Pascal Soriot is still hard at work in patching up AstraZeneca's (NYSE:AZN) battered pipeline and five-year profit prospects. Following the announcement of an agreement to acquire Omthera (Nasdaq:OMTH) to boost the company's cardiovascular drug business, AstraZeneca announced Monday that it was acquiring development-stage COPD drug developer Pearl Therapeutics. While AstraZeneca does not appear to be buying a future blockbuster, the deal should be a relatively low-risk way to boost the company's important respiratory drug franchise and offset some of the downside risk to the five-year revenue and profit outlook.
Please continue reading here:
http://www.investopedia.com/stock-analysis/061013/astrazeneca-pays-patch-another-key-area-azn-gsk-thrx-nvs-frx.aspx
Investopedia: AstraZeneca Pays Up To Patch Up Another Key Area
0 comments:
Post a Comment